PT - JOURNAL ARTICLE AU - Kleinecke, Mariana AU - Rumaseb, Angela AU - Sutanto, Edwin AU - Trimarsanto, Hidayat AU - Hoon, Kian Soon AU - Osborne, Ashley AU - Manrique, Paulo AU - Peters, Trent AU - Hawkes, David AU - Benavente, Ernest Diez AU - Whitton, Georgia AU - Siegel, Sasha V AU - Pearson, Richard D AU - Amato, Roberto AU - Rai, Anjana AU - Thuy Nhien, Nguyen Thanh AU - Chau, Nguyen Hoang AU - Assefa, Ashenafi AU - Degaga, Tamiru S AU - Abate, Dagimawie Tadesse AU - Rahim, Awab Ghulam AU - Pasaribu, Ayodhia Pitaloka AU - Sutanto, Inge AU - Alam, Mohammad Shafiul AU - Pava, Zuleima AU - Mesa, Tatiana Lopera- AU - Echeverry, Diego AU - William, Tim AU - Anstey, Nicholas M AU - Grigg, Matthew J AU - Day, Nicholas AU - White, Nicholas J. AU - Kwiatkowski, Dominic P AU - Noviyanti, Rintis AU - Neafsey, Daniel AU - Price, Ric N AU - Auburn, Sarah TI - Microhaplotype deep sequencing assays to capture <em>Plasmodium vivax</em> infection lineages AID - 10.1101/2024.10.14.24315131 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.14.24315131 4099 - http://medrxiv.org/content/early/2024/10/18/2024.10.14.24315131.short 4100 - http://medrxiv.org/content/early/2024/10/18/2024.10.14.24315131.full AB - The elimination of Plasmodium vivax is challenged by dormant liver stages (hypnozoites) that can reactivate months after initial infection resulting in relapses that enhance transmission. Relapsing infections confound antimalarial clinical efficacy trials due to the inability to distinguish between recurrences arising from blood-stage treatment failure (recrudescence), reinfection or relapse. Genetic relatedness of paired parasite isolates, measured by identity-by-descent (IBD), can provide important information on whether individuals have had single or multiple mosquito inoculations, thus informing on recurrence origin. We developed a high-throughput amplicon sequencing assay comprising 93 multi-SNP (microhaplotype) P. vivax markers to determine IBD between P. vivax clinical isolates. The assay was evaluated in 659 independent infections from the Asia-Pacific and Horn of Africa, including 108 pairs of infections from a randomized controlled trial (RCT). A bioinformatics pipeline (vivaxGEN-MicroHaps) was established to support data processing. Simulations using paneljudge demonstrated low error in pairwise IBD estimation in all countries assessed (all RMSE &lt;0.12) and IBD-based networks illustrated strong clustering by geography. IBD analysis in the RCT demonstrated a higher frequency of suspected relapses or recrudescence in patients treated with primaquine regimens (0.84) compared to those without primaquine (0.60). Our results demonstrate the potential to derive information on P. vivax IBD using amplicon sequencing, that informs policy-relevant treatment and transmission dynamics.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://github.com/vivaxgen/MicroHaps https://www.protocols.io/file/rfffce597.pdf Funding StatementThis work was supported, in whole or in part, by the Bill &amp; Melinda Gates Foundation INV-043618 (supporting S.A., D.N and R.N.P). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. The study was also supported by the National Health and Medical Research Council of Australia (APP2001083 supporting S.A. and S.V.S.). The whole genome sequencing component of the study was supported by the Medical Research Council and UK Department for International Development (award number M006212 to D.K.) and the Wellcome Trust (award numbers 206194 and 204911 to D.K.). The OPRA clinical trial was supported by the Bill &amp; Melinda Gates Foundation (OPP1054404 awarded to R.N.P.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples in this study were derived from blood samples obtained from patients positive for malaria and collected with informed consent from the patient, or patient parent / legal guardian where individuals were less than 18 years of age. At each location, sample collection was approved by the appropriate institutional ethics committees. The following committees gave ethical approval for the partner studies: Human Research Ethics Committee of Northern Territory Department of Health and Families and Menzies School of Health Research, Darwin, Australia; Islamic Republic of Afghanistan Ministry of Public Health Institutional Review Board, Afghanistan; International Centre for Diarrheal Disease Research, Bangladesh Ethical Review Committee; Research Ethics Board of Health, at the Ministry of Health in Bhutan; Comite Institucional de Etica de Investigaciones en Humanos, Colombia; Comite de Bioetica Instituto de Investigaciones Medicas Facultad de Medicina Universidad de Antioquia, Colombia; Armauer Hansen Research Institute Institutional Review Board, Ethiopia; Addis Ababa University College of Natural Sciences, Ethiopia; Addis Ababa University, Aklilu Lemma Institute of Pathobiology Institutional Review Board, Ethiopia; National Research Ethics Review Committee of Ethiopia; Eijkman Institute Research Ethics Committee, Jakarta, Indonesia; Research Review Committee of the Institute for Medical Research and the Medical Research Ethics Committee (MREC), Ministry of Health, Malaysia; Scientific and Ethical Committee of the Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam; The Ministry of Health Evaluation Committee on Ethics in Biomedical Research, Vietnam.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe MalariaGEN Pv4.0 WGS data are available through the European Nucleotide Archive. The WGS reads from the newly generated, high-quality, Ethiopian P. vivax infections are available through the European Nucleotide Archive. The ENA accession numbers for all WGS samples used here are listed in Supplementary Data 7. All high-quality (pass) microhaplotype-based parasite reads will be made available in the European Nucleotide Archive at publication (Supplementary Data 2). https://www.malariagen.net/data_package/open-dataset-plasmodium-vivax-v4-0/ The MalariaGEN Pv4.0 WGS data are available through the European Nucleotide Archive 38. The WGS reads from the newly generated, high-quality, Ethiopian P. vivax infections are available through the European Nucleotide Archive. The ENA accession numbers for all WGS samples used here are listed in Supplementary Data 7. All high-quality (pass) microhaplotype-based parasite reads will be made available in the European Nucleotide Archive at publication (Supplementary Data 2).